![]() |
市场调查报告书
商品编码
1827767
2025年全球眼部植入市场报告Ocular Implants Global Market Report 2025 |
近年来,眼部植入市场快速扩张,市场规模从2024年的147.6亿美元成长至2025年的162.5亿美元,复合年增长率为10.1%。预测期内的成长主要归因于眼部外伤、视力矫正、糖尿病视网膜病变、眼科疾病以及监管核准。
预计未来几年眼部植入市场将快速成长,到2029年将达到250.6亿美元,复合年增长率为11.4%。预测期内的成长归因于人口老化加剧、近视盛行率上升、青光眼管理、微创手术以及病人安全。预测期内的主要趋势包括技术进步、眼科创新、数位医疗、再生医学、数位医疗和人工智慧 (AI)。
眼部植入用于增强个人视力。这些植入有助于因受伤或疾病而失去眼睛的人恢復视力。这些植入物通常被称为玻璃眼,由硬质塑胶丙烯酸製成。义眼呈贝壳状,内含透明的人工水晶体植入,用于在白内障手术中替换混浊的自然水晶体。
眼部植入的主要产品类型包括人工水晶体、角膜植入、眼眶植入和青光眼植入。人工水晶体由透明塑胶、硅胶和丙烯酸等材料製成。这些水晶体屈光进入眼睛的光线,从而改善视力。此外,它们还涂有特殊材料,以保护眼睛免受太阳发出的有害紫外线的伤害。眼部植入被眼科机构、医院和诊所等终端使用者用于治疗青光眼、糖尿病视网膜病变和老龄化性黄斑部病变。
2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备产业产生了重大影响,尤其对影像处理设备、手术用不銹钢和一次性塑胶等进口零件产生了重大影响。由于医院和诊所抵制涨价,製造商面临利润压力。监管挑战进一步加剧了形势,因为由于关税而更换供应商通常需要医疗设备重新认证,导致市场准入延迟。为此,企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。
本研究报告是商业研究公司 (The Business Research Company) 全新报告系列的一部分,该系列提供眼部植入市场统计数据,包括全球眼部植入市场规模、各地区市场份额、竞争对手的眼部植入市场份额、详细的眼部植入细分市场、市场趋势和商机,以及您在眼部植入行业取得成功所需的数据。本眼部植入市场研究报告对该行业的现状和未来趋势进行了详细分析,为您提供所需的全方位观点。
未来五年的预测成长率为11.4%,较我们先前对该市场的预测略有下降0.1%。这一下降主要源自于美国与其他国家之间关税的影响。由于互惠关税以及贸易紧张局势和限制措施的加剧对全球经济和贸易的负面影响,其影响将更加广泛。
全球老年人口的成长预计将推动未来眼部植入市场的成长。老年人口通常指65岁及以上的人。眼部植入为常见的与老龄化相关的眼部疾病(如白内障、青光眼和老花眼)提供了解决方案,可以改善视力,减少对矫正眼镜的需求,并提高老年人的生活品质。例如,2022年10月,总部位于瑞士的国际公共卫生组织世界卫生组织(WHO)预测,全球60岁以上人口将从2020年的10亿增加到2022年的14亿。此外,据估计,到2030年,全球六分之一的人将年满60岁或以上。因此,全球老年人口的成长可能会刺激眼部植入市场的扩张。
全球范围内眼科疾病的日益流行预计将极大地推动眼部植入市场的成长。在美国最常见的眼科疾病包括屈光不正。例如,2022 年,美国眼科学会 (AAO) 提供了按种族分類的与眼部疾病相关的视力障碍盛行率的统计数据,以及因这些疾病而法定失明的人数数据。光是在美国,就有大约 1,200 万 40 岁及以上的人患有视力障碍,而全球整体约有 100 万人失明。此外,根据世界卫生组织 (WHO) 的数据,全世界约有 22 亿人患有眼睛或视力障碍。因此,预计白内障和青光眼等眼科疾病的盛行率将会上升,从而推动对眼部植入的需求。
眼部植入市场的主要企业专注于创造创新解决方案,例如Axitinib玻璃体内植入,以改善视网膜静脉阻塞和糖尿病性黄斑部水肿等眼科疾病的治疗选择。Axitinib体内植入是一种小型药物释放装置,直接插入眼部玻璃体腔,以受控、持续的方式输送蛋白酪氨酸激酶抑制剂Axitinib。例如,美国製药公司 Ocular Therapeutix, Inc. 已启动其Axitinib体内植入物 (OTX-TKI) 治疗湿性老龄化黄斑部病变(湿性 AMD) 的关键临床试验。该试验旨在评估与阿柏西普标准治疗相比,植入在保护视力方面的安全性和有效性。该试验计划为一项多中心、随机试验,涉及约 300 名患者,旨在探索 OTX-TKI药物缓释的潜力,从而减少有效治疗所需的注射频率。
眼科植入市场的主要企业正在推出创新的高品质虹膜植入产品,例如 ARTIFICIALIRIS SELECT,以获得竞争优势。 ARTIFICIALIRIS SELECT 是一种高级植入,可提供快速、可自订的虹膜更换并增强患者护理。例如,德国医疗技术製造商 HumanOptics Holding AG 计划于 2023 年 8 月推出其高级植入ARTIFICIALIRIS SELECT。该植入将提供多种颜色,包括棕色、蓝色和绿色,每种颜色都有三种色调:浅色、中型和深色。此外,该植入将提供九种预先定义的颜色组合,确保快速有效地治疗患者。外科医生可以使用专门设计的 HumanOptics Color Chart SELECT 将色卡与患者的健康眼睛进行比较,轻鬆为患者选择最合适的颜色。
2024年6月,美国製药公司ANI Pharmaceuticals, Inc.收购了Alimera Sciences, Inc.,收购金额未揭露。此次收购将增强ANI Pharmaceuticals在罕见疾病和眼科领域的产品组合,使其能够获得两项实用化的资产—Iluvien和Yutiq。预计这两项资产将带来显着的收益成长,并提升ANI Pharmaceuticals在眼科领域的全球影响力。 Alimera Sciences, Inc.也是一家总部位于美国的製药公司,专注于眼内植入。
眼部植入市场的主要企业包括 Alcon Inc.、Bausch & Lomb Inc.、Carl Zeiss AG、STAAR Surgical Company、Johnson and Johnson Services Inc.、Morcher GmbH、Aurolab Ltd.、Cornea Biosciences、KERAMED INC.、Price Vision Group、Gulden Ophan Ophatics Co.Owacyk、Jkak但是、Lomu 哇Inc.、SIFI SpA、Ophtec BV、HumanOptics AG、Medicontur Medical Engineering Ltd.、Hanita Lenses、Omni Lens Pvt. Ltd.、EyeKon Medical Inc.、FCI Ophthalmics Inc.、Santen Pharmaceutical Co. Ltd.、Ocular Therapeuvan Inc.、AcuFocus Inc.
2024年,北美是眼部植入市场最大的地区。预计亚太地区将成为预测期内成长最快的地区。眼部植入市场份额报告涵盖亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。
眼植入市场报告涉及的国家有澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国和美国。
眼部植入市场涵盖单焦点、散光镜片、多焦点和可调节晶体的销售。该市场的价值指的是“出厂价”,即商品製造商或生产商销售给其他营业单位(包括下游製造商、批发商、经销商和零售商)或直接销售给最终客户的商品价值。该市场中的商品价值还包括商品製造商销售的任何相关服务。
Ocular implants are employed to enhance the vision of individuals. These implants contribute to the restoration of sight in those who have lost an eye due to injury or disease, commonly known as a glass eye, typically crafted from hard plastic acrylic. The prosthetic eye takes the form of a shell, incorporating a clear, artificial lens implant utilized to substitute a clouded natural lens during cataract surgery.
The primary product categories within ocular implants encompass intraocular lenses, corneal implants, orbital implants, glaucoma implants, and others. Intraocular lenses are fashioned from materials such as clear plastic, silicone, or acrylic. These lenses refract light rays entering the eye, facilitating improved vision. Additionally, they are coated with a special material designed to shield the eyes from the harmful ultraviolet rays emitted by the sun. Ocular implants find application in procedures related to glaucoma, diabetic retinopathy, and age-related macular degeneration, and are utilized by end-users such as specialty eye institutes, hospitals, and clinics.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The ocular implants market research report is one of a series of new reports from The Business Research Company that provides ocular implants market statistics, including ocular implants industry global market size, regional shares, competitors with a ocular implants market share, detailed ocular implants market segments, market trends and opportunities, and any further data you may need to thrive in the ocular implants industry. This ocular implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ocular implants market size has grown rapidly in recent years. It will grow from $14.76 billion in 2024 to $16.25 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to ocular trauma, vision correction, diabetic retinopathy, eye diseases, regulatory approvals.
The ocular implants market size is expected to see rapid growth in the next few years. It will grow to $25.06 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growing aging population, rising myopia prevalence, glaucoma management, minimally invasive surgery, patient safety. Major trends in the forecast period include technological advancements, ophthalmic innovation, digital healthcare, regenerative medicine, digital healthcare, artificial intelligence (ai).
The forecast of 11.4% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through trade restrictions on German-sourced acrylic polymers, raising production costs for intraocular lenses and potentially delaying cataract surgery procedures for aging populations.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increase in the global geriatric population is anticipated to drive the growth of the ocular implants market in the future. The geriatric population refers to individuals typically aged 65 and older. Ocular implants offer solutions for common age-related eye conditions such as cataracts, glaucoma, and presbyopia, helping to improve vision, decrease the need for corrective eyewear, and enhance the quality of life for older adults. For example, in October 2022, the World Health Organization, an international public health organization based in Switzerland, projected that the global population of individuals aged 60 years and older would rise to 1.4 billion by 2022, up from 1 billion in 2020. Furthermore, by 2030, it is estimated that 1 in 6 people worldwide will be over 60 years of age. Thus, the growth of the geriatric population globally will stimulate the expansion of the ocular implants market.
The growing prevalence of eye disorders worldwide is expected to significantly drive the growth of the ocular implants market. The most common eye disorders in the U.S. include refractive errors. For example, in 2022, the American Academy of Ophthalmology (AAO) provided statistics on the prevalence of visual impairments related to eye disorders by ethnicity, as well as data on the number of individuals who are legally blind due to these conditions. In the United States alone, approximately 12 million people aged 40 and older experience vision impairment, with about one million suffering from blindness globally. Furthermore, reports indicate that around 2.2 billion individuals worldwide have eye and visual disorders, according to the World Health Organization. Consequently, the rising prevalence of eye disorders, including cataracts and glaucoma, is anticipated to increase the demand for ocular implants.
Major companies in the ocular implants market are concentrating on creating innovative solutions, such as axitinib intravitreal implants, to improve treatment options for eye diseases like retinal vein occlusion and diabetic macular edema. Axitinib intravitreal implants are small, drug-releasing devices inserted directly into the eye's vitreous cavity to deliver axitinib, a tyrosine kinase inhibitor, in a controlled and sustained manner. For example, Ocular Therapeutix, Inc., a U.S.-based pharmaceutical company, has initiated a pivotal clinical trial for its axitinib intravitreal implant, OTX-TKI, intended for the treatment of wet age-related macular degeneration (wet AMD). This trial aims to evaluate the safety and efficacy of the implant in preserving visual acuity compared to the standard treatment with aflibercept. Designed as a multi-center, randomized study involving approximately 300 patients, the trial seeks to determine the potential of OTX-TKI to provide a sustained release of the drug, which may reduce the frequency of injections needed for effective treatment.
Major companies in the ocular implant market are launching innovative and high-quality iris implant products, such as ARTIFICIALIRIS SELECT, to achieve a competitive edge. ARTIFICIALIRIS SELECT is a premium implant that provides expedited and customizable iris replacement to enhance patient care. For instance, in August 2023, HumanOptics Holding AG, a Germany-based medical technology manufacturer, is set to introduce the premium implant ARTIFICIALIRIS SELECT. This implant offers a variety of color options, including brown, blue, and green, each available in three different shades: light, medium, and dark. Additionally, the implant comes in nine predefined color combinations, ensuring prompt and efficient patient care. Surgeons can easily choose the most suitable color match for the patient by utilizing the specially designed HumanOptics Color Chart SELECT, allowing them to compare it with the patient's healthy eye.
In June 2024, ANI Pharmaceuticals, Inc., a US-based pharmaceutical company, acquired Alimera Sciences, Inc., for an undisclosed sum. This acquisition is intended to strengthen ANI Pharmaceuticals' rare disease segment and ophthalmology portfolio, providing access to two commercially viable assets, Iluvien and Yutiq, which are anticipated to drive substantial revenue growth and enhance ANI's global footprint in the ophthalmology market. Alimera Sciences, Inc., also a US-based pharmaceutical company, specializes in intravitreal (back of the eye) implants.
Major companies operating in the ocular implants market include Alcon Inc., Bausch & Lomb Inc., Carl Zeiss AG, STAAR Surgical Company, Johnson and Johnson Services Inc., Morcher GmbH, Aurolab Ltd., Cornea Biosciences, KERAMED INC., Price Vision Group, Gulden Ophthalmics Co. Inc., AJL Ophthalmic SA, Hoya Corp., Rayner Intraocular Lenses Limited, Lenstec Inc., SIFI S.p.A, Ophtec BV, HumanOptics AG, Medicontur Medical Engineering Ltd., Hanita Lenses, Omni Lens Pvt. Ltd., EyeKon Medical Inc., FCI Ophthalmics Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., AcuFocus Inc., Glaukos Corporation, Ivantis Inc.
North America was the largest region in the ocular implants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ocular implants market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the ocular implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The ocular implants market consists of sales of monofocal lens, toric lens, multifocal and accommodating lenses. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ocular Implants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ocular implants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for ocular implants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ocular implants market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.